The development program of AER-901, Aerami Therapeutics’ inhaled formulation of imatinib, will include pulmonary hypertension associated with interstitial lung disease (PH-ILD). According to the company, data from a completed Phase 1 clinical trial support the progression of AER-901 into Phase 2 trials for pulmonary arterial hypertension (PAH)…
A peptide called apelin-17 may be used as a diagnostic biomarker for idiopathic pulmonary arterial hypertension (IPAH), according to the results of a new study. Apelin-17 levels were found to detect IPAH with an accuracy similar to NT-proBNP and GDF-15 — two established biomarkers for pulmonary hypertension (PH)…
Treatment with swietenine — extracted from the seeds of Swietenia macrophylla, a tree commonly called mahogany — eased the remodeling of lung blood vessels in a mouse model of pulmonary hypertension (PH). Researchers in China found that swietenine worked against this disease hallmark by inhibiting the growth of smooth muscle cells…
Pulmonary arterial hypertension (PAH) is associated with high utilization of healthcare resources by patients and with productivity loss, starting years before diagnosis, according to a study in Sweden. “The economic and clinical burden associated with PAH suggests that strategies for earlier diagnosis and more effective treatments are warranted,” researchers…
Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new subcutaneous or under-the-skin infusion pump for treprostinil — a generic form of Remodulin — for treating people with pulmonary arterial hypertension (PAH). The exclusive rights to promote and market treprostinil injection belong…
Despite treatment advances in pulmonary hypertension (PH) over the last two decades, the age-adjusted PH-related death rate in the U.S. increased annually between 1999 and 2019, with mortality climbing by nearly 2% each year, a new study found. The simultaneous presence of PH and disease of the left side…
Get regular updates to your inbox.